Cerevel Therapeutics develops new treatments for diseases related to the brain and nervous system. The company focuses on conditions like Parkinson's disease, epilepsy, and schizophrenia, using a combination of advanced chemistry and the study of how drugs interact with brain receptors. Unlike many competitors, Cerevel emphasizes a deep understanding of brain biology and neurocircuitry to guide its drug development process. The goal is to create effective therapies for the millions of people affected by these challenging conditions, with a commitment to rigorous research and clinical trials.

AbbVie

EcoR1 Capital

Pfizer

Ally Bridge Group

Invus

Novalis Lifesciences

Perceptive Advisors

Adage Capital

Federated Hermes

Bain Capital

Sphera Global Healthcare Fund

Boxer Capital

Surveyor Capital

T. Rowe Price

RA Capital Management

Fidelity Investments

Rock Springs Capital

Arya Sciences Acquisition II

Biotechnology

Healthcare

Cerevel Therapeutics

AbbVie's experimental schizophrenia drug, emraclidine, acquired through a $9 billion purchase of Cerevel Therapeutics, failed to show significant patient improvement in Phase 2 trials using the PANSS test compared to a placebo. AbbVie's chief scientific officer, Roopal Thakkar, expressed disappointment and stated that the company is analyzing the data to determine next steps.

AbbVie’s $9B Schizophrenia Drug Fails Trials

AbbVie has completed the acquisition of Cerevel Therapeutics, a company with a portfolio of neurological and psychiatric products. AbbVie acquired all outstanding shares of Cerevel for $45 (€40.47) each. Cerevel's shares ceased trading on NASDAQ on August 1, 2024. AbbVie expects the acquisition to increase earnings per share starting in 2030.

AbbVie Acquires Cerevel for $45/Share

Cerevel, meanwhile, was acquired by AbbVie for $8.7 billion.

Bain closes $3B biotech fund amid flurry of startup buyouts

AbbVie has completed its acquisition of Cerevel Therapeutics for approximately $8.7 billion-strengthening its foundation in neuroscience and positioning itself to deliver sustainable long-term performance.

AbbVie Acquires Cerevel Therapeutics

AbbVie's acquisition of Cerevel Therapeutics for nearly $9 billion, announced in December 2023, is expected to close soon, potentially as early as next week, despite an FTC "second request" for additional information in February. AbbVie CEO Rob Michael confirmed substantial compliance with the FTC's request and no expected divestments. Cerevel will become a subsidiary of AbbVie, enhancing its neuroscience franchise. Cerevel’s stock rose 2.4%, and AbbVie’s rose 3.4% post-announcement.

AbbVie to Acquire Cerevel for $9B

Pictured: Images of brain taken from MRI scans/iStock, Nur Ceren DemirCerevel Therapeutics on Thursday reported topline data from the Phase III TEMPO-3 trial, demonstrating that its investigational Parkinson’s disease therapy tavapadon can significantly improve the control of motor symptoms when used with levodopa.At 27 weeks, patients on tavapadon plus levodopa saw a 1.7-hour increase in total “on” time without troublesome dyskinesia. In Parkinson’s disease, on time refers to periods of good symptom control, when patients can move and function properly. This effect was nearly three times greater in TEMPO-3 than patients who were given placebo on top of levodopa, in whom this measure improved by only 0.6 hours.The treatment effect of 1.1 hours was “clinically meaningful and statistically significant,” with a p-value less than 0.0001, according to Cerevel.Tavapadon treatment also resulted in significantly lower “off” time, which refers to periods when medication is starting to wear off and symptoms become more noticeable and difficult. In the trial, tavapadon was also safe and well-tolerated, with most of its side effects being mild or moderate in severity.Cerevel CMO Raymond Sanchez in a statement said that the company is “highly encouraged” by TEMPO-3’s results, which he added has shown that tavapadon has “the potential to provide people living with Parkinson’s disease the right balance of motor control, safety and tolerability.” Data from Thursday’s readout will support regulatory submissions for tavapadon, according to Cerevel.Tavapadon is a potentially first-in-class selective partial agonist of the D1/D5 receptors, which are dopamine receptor subtypes that directly regulate motor activity, according to Cerevel’s website. This mechanism of action allows tavapadon to specifically activate the brain’s motor pathways while minimizing side effects such as sleepiness, sedation, hallucinations and impaired impulse control.Significantly, tavapadon maximizes the activation of D1/D5 receptors while avoiding prolonged hyper-excitation, which typically leads to dyskinesias and “off” time.Cerevel is currently testing tavapadon the Phase III TEMPO clinical development program. The late-stage trial is an adjunctive study and is designed to evaluate tavapadon when combined with levodopa

Cerevel Gets Phase Iii Parkinson’S Win On Heels Of $8.7B Abbvie Acquisition

Pictured: Fractured time and melting clock/Taylor Tieden for BioSpaceWhile the past few decades have seen a focus on treating Alzheimer's disease at the source, which is widely considered to be the build-up of amyloid fibrils and tau tangles, many companies are also chasing the first approval of a drug to treat the related psychosis. Anti-amyloid drugs like Eisai and Biogen’s Leqembi and Eli Lilly’s donanemab represent a leap forward, but many experts say success rates are modest, and Aduhelm, Biogen and Eisai’s first anti-amyloid treatment, was discontinued in January.Against this backdrop, companies are increasingly focusing on symptomatic treatments, said Graig Suvannavejh, a senior biopharmaceuticals and biotechnology equity research analyst at Mizuho Americas. Using a financial model, Suvannavejh estimated that 35% of Alzheimer’s patients have psychosis. Even discounting patients who may not be diagnosed or have access to treatments, this translates to roughly 1 million patients in the U.S. alone, making for a large market opportunity, he told BioSpace.Unconventional TargetsAccording to ClinicalTrials.gov, there are more than 600 active trials studying interventional treatments for Alzheimer’s disease, but fewer than 30 that focus on Alzheimer’s-related psychosis.Given the lack of options, Alzheimer’s patients who experience psychosis may be prescribed off-label antipsychotics approved for schizophrenia, said Christoph Correll, a professor of psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.Most antipsychotics target the receptors of dopamine and serotonin, neurotransmitters that are common to many processes in the body. Because of this overlap between molecular pathways in the brain and the rest of the body, the drugs can cause side effects like excessive sleepiness, swallowing difficulties and uncontrolled movements. These effects make compliance an issue for Alzheimer’s patients in particular, who are likely on other medications and may be unwilling to tolerate additional side effects, Correll said.Christiana Bardon, a co-managing partner at MPM BioImpact, told BioSpace that the side effects associated with all antipsychotics are a significant complaint

Psychosis: The Other Big Alzheimer’S Therapeutic Target

Earlier in December, AbbVie (ABBV Quick QuoteABBV - Free Report) signed a definitive agreement to acquire neuroscience drugmaker Cerevel Therapeutics (CERE Quick QuoteCERE - Free Report) for $8.7 billion.

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

The deal also closely follows an $8.7 billion deal by AbbVie to acquire Cerevel Therapeutics, which has a similar, rival drug to Karuna's in advanced testing.

Bristol Myers to acquire brain drug developer Karuna for $14B

In December so far, Danaher Corporation (NYSE:DHR) completed the acquisition of Abcam plc (NASDAQ:ABCM), a protein consumables supplier, for $5.7 billion, while AbbVie Inc. (NYSE:ABBV) announced an agreement to acquire Cerevel Therapeutics (NASDAQ:CERE) for nearly $8.7 billion in cash.

12 Healthcare Stocks Billionaires Like the Most

Develops treatments for neuroscience diseases

Cerevel Therapeutics

Develops treatments for neuroscience diseases

Cerevel Therapeutics

Develops treatments for neuroscience diseases

About

Simplify's Take

What believers are saying

What critics are saying

What makes Cerevel Therapeutics unique

6 month growth

1 year growth

2 year growth

Recently Posted Jobs

There are no jobs for Cerevel Therapeutics right now.